Product Information
OLANZAPINE-FLUOXETINE 12-25 MG is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $9.9295 per EA under NDC 00093550656. Its NADAC has been published 333 times since Jan 22, 2014.
FDA first approved this application on Jun 19, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 12 mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093550656
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FLUOXETINE HYDROCHLORIDE; OLANZAPINEApproval Type
Generic (ANDA)
FDA Application
ANDA077528FDA Approved
6/19/2012
TE Code
AB
On Market Since
6/19/2012
Pharmacological Classes
Price Statistics
The NADAC for OLANZAPINE-FLUOXETINE 12-25 MG has been published 333 times since Jan 22, 2014, and over the history we have for it it has declined 40.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.9295 per EA |
|---|---|
| All-time high | $17.0031 (Aug 13, 2014) |
| All-time low | $6.2827 (Jul 23, 2025) |
| 52-week high | $9.9295 |
| 52-week low | $6.6384 |
| Median price | $13.1290 |
| Average price | $11.6102 |
| Largest weekly change | -48.9% (Dec 19, 2018) |
| Weeks tracked | 333 |
| Tracking since | Jan 22, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Olanzapine and Fluoxetine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Olanzapine and Fluoxetine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OLANZAPINE-FLUOXETINE 12-25 MG?
The current National Average Drug Acquisition Cost (NADAC) for OLANZAPINE-FLUOXETINE 12-25 MG, manufactured by Teva Pharmaceuticals USA Inc., is $9.9295 per EA (NDC 00093550656), effective Sep 30, 2026.
How has the price of OLANZAPINE-FLUOXETINE 12-25 MG changed over time?
Over the history we have for it, the NADAC for OLANZAPINE-FLUOXETINE 12-25 MG has declined 40.6%. It has been tracked across 333 weekly CMS publications since Jan 22, 2014.
What are the highest and lowest recorded NADAC prices for OLANZAPINE-FLUOXETINE 12-25 MG?
Since Jan 22, 2014, the NADAC for OLANZAPINE-FLUOXETINE 12-25 MG has ranged from a low of $6.2827 (Jul 23, 2025) to a high of $17.0031 (Aug 13, 2014), with a median of $13.1290 per EA.
Are there cheaper alternatives to OLANZAPINE-FLUOXETINE 12-25 MG?
No other NADAC-published product currently shares the active ingredient and strength of OLANZAPINE-FLUOXETINE 12-25 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OLANZAPINE-FLUOXETINE 12-25 MG?
OLANZAPINE-FLUOXETINE 12-25 MG (NDC 00093550656) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.